📊 IMNN Key Takeaways
Is Imunon, Inc. (IMNN) a Good Investment?
Imunon faces critical cash runway depletion with $14.2M annual free cash flow burn against only $8.8M cash reserves, providing less than 12 months of operations without external funding. The company generates merely $500K in annual revenue against $14.5M in net losses, indicating a pre-commercial product stage with no demonstrated path to profitability. Unsustainable capital structure cannot support $6.1M long-term debt from operations, creating acute refinancing and dilution risk.
Imunon shows minimal revenue and extremely negative profitability, indicating a pre-commercial profile dependent on external funding. While liquidity is currently adequate, cash covers less than a year of burn and interest coverage is deeply negative, raising refinancing and dilution risks. Without a clear path to revenue inflection or substantial non-dilutive funding, sustained losses are likely.
Why Buy Imunon, Inc. Stock? IMNN Key Strengths
- Improving loss trajectory YoY (22.2% net income improvement, 59.7% EPS improvement) demonstrates cost discipline
- Solid near-term liquidity with 2.32x current ratio and 2.32x quick ratio providing near-term solvency cushion
- Moderate leverage at 0.86x debt-to-equity with minimal capex ($280.6K) appropriate for development stage
- Solid near-term liquidity (current ratio 2.32x)
- Cash-heavy asset base with low capex needs
- Improving net loss/EPS trend YoY
IMNN Stock Risks: Imunon, Inc. Investment Risks
- Critical cash runway - $8.8M cash against $14.2M annual FCF burn creates sub-12-month survival horizon without capital raise
- Revenue generation failure - $500K revenue against $14.5M net loss indicates pre-commercial development stage with unproven market traction
- Debt servicing crisis - negative $74.3x interest coverage ratio means operating income cannot service $6.1M long-term debt obligations
- Imminent equity dilution risk - company will require near-term capital raises to fund operations, destroying existing shareholder value
- De minimis, flat revenue base drives funding dependence
- High cash burn and deeply negative margins shorten runway
- Leverage with negative interest coverage heightens refinancing/dilution risk
Key Metrics to Watch
- Monthly cash burn rate and ending cash balance - critical indicator of runway to funding need
- Revenue growth and product commercialization milestones - only measure of fundamental viability
- Debt refinancing announcements and terms - indicates market access to capital and covenant compliance
- Operating cash flow (TTM burn)
- Cash & equivalents and runway months
Imunon, Inc. (IMNN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.32x current ratio provides a solid financial cushion.
IMNN Profit Margin, ROE & Profitability Analysis
IMNN vs Healthcare Sector: How Imunon, Inc. Compares
How Imunon, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Imunon, Inc. Stock Overvalued? IMNN Valuation Analysis 2026
Based on fundamental analysis, Imunon, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Imunon, Inc. Balance Sheet: IMNN Debt, Cash & Liquidity
IMNN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Imunon, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-16.94 indicates the company is currently unprofitable.
IMNN Revenue Growth, EPS Growth & YoY Performance
IMNN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $125.0K | -$3.5M | $-0.37 |
| Q2 2023 | $125.0K | -$5.5M | $-0.61 |
| Q1 2023 | $125.0K | -$5.5M | $-0.68 |
| Q3 2022 | $125.0K | -$5.4M | $-0.87 |
| Q2 2022 | $125.0K | -$5.4M | $-0.87 |
| Q1 2022 | $125.0K | -$5.7M | $-1.82 |
| Q3 2021 | $125.0K | -$5.4M | N/A |
| Q2 2021 | $125.0K | -$5.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Imunon, Inc. Dividends, Buybacks & Capital Allocation
IMNN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Imunon, Inc. (CIK: 0000749647)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMNN
What is the AI rating for IMNN?
Imunon, Inc. (IMNN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMNN's key strengths?
Claude: Improving loss trajectory YoY (22.2% net income improvement, 59.7% EPS improvement) demonstrates cost discipline. Solid near-term liquidity with 2.32x current ratio and 2.32x quick ratio providing near-term solvency cushion. ChatGPT: Solid near-term liquidity (current ratio 2.32x). Cash-heavy asset base with low capex needs.
What are the risks of investing in IMNN?
Claude: Critical cash runway - $8.8M cash against $14.2M annual FCF burn creates sub-12-month survival horizon without capital raise. Revenue generation failure - $500K revenue against $14.5M net loss indicates pre-commercial development stage with unproven market traction. ChatGPT: De minimis, flat revenue base drives funding dependence. High cash burn and deeply negative margins shorten runway.
What is IMNN's revenue and growth?
Imunon, Inc. reported revenue of $500.0K.
Does IMNN pay dividends?
Imunon, Inc. does not currently pay dividends.
Where can I find IMNN SEC filings?
Official SEC filings for Imunon, Inc. (CIK: 0000749647) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMNN's EPS?
Imunon, Inc. has a diluted EPS of $-6.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMNN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Imunon, Inc. has a STRONG SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMNN stock overvalued or undervalued?
Valuation metrics for IMNN: ROE of -205.3% (sector avg: 15%), net margin of -2,899.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMNN stock in 2026?
Our dual AI analysis gives Imunon, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMNN's free cash flow?
Imunon, Inc.'s operating cash flow is $-13.9M, with capital expenditures of $280.6K. FCF margin is -2,835.4%.
How does IMNN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,899.0% (avg: 12%), ROE -205.3% (avg: 15%), current ratio 2.32 (avg: 2).